BLOOMAGE BIOTECHNOLOGY CORP LTD Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Bloomage BioTechnology Corporation Limited華 熙 生 物 科 技 有 限 公 司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 00963) RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2016 FINANCIAL HIGHLIGHTSRevenue of the Group for the year ended 31 December 2016 was approximately RMB844,388,000, representing an increase of approximately RMB193,520,000 or 29.7% compared with the corresponding period in 2015.
Profit attributable to equity shareholders of the Company for the year ended 31 December 2016 was approximately RMB228,101,000, representing an increase of approximately RMB37,708,000 or 19.8% compared with the corresponding period in 2015.
The earnings before interest, taxes, depreciation and amortisation (excluding share of profits less losses of associates and share of loss of a joint venture) of the Group for the year ended 31 December 2016 was approximately RMB363,407,000 (2015: approximately RMB290,997,000), representing an increase of approximately RMB72,410,000 or 24.9% as compared to 2015.
The Board recommends a final dividend of HK$3.1 cents per share for the year ended 31 December 2016 (2015: HK$2.7 cents per share).
The board (the "Board") of directors (the "Directors") of Bloomage BioTechnology Corporation Limited (the "Company") is pleased to announce the audited consolidated results of the Company and its subsidiaries (collectively, the "Group") for the year ended 31 December 2016, together with comparative figures for the year ended 31 December 2015 as follows:
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME for the year ended 31 December 20162016 | 2015 | |||
Note | RMB'000 | RMB'000 | ||
Revenue | 4 | 844,388 | 650,868 | |
Cost of sales | (251,959) | (163,629) | ||
Gross profit | 592,429 | 487,239 | ||
Other revenue | 5 | 26,752 | 15,799 | |
Distribution costs | (128,744) | (107,070) | ||
Administrative expenses | (175,753) | (141,910) | ||
Other operating (expenses)/income, net | (932) | 569 | ||
Profit from the operation | 313,752 | 254,627 | ||
Finance costs | 6(a) | (45,383) | (16,727) | |
Share of profits less losses of associates | 20,481 | 91 | ||
Share of loss of a joint venture | (27) | (66) | ||
Profit before taxation | 6 | 288,823 | 237,925 | |
Income tax | 7 | (60,723) | (47,530) | |
Profit for the year | 228,100 | 190,395 | ||
Other comprehensive income for the year | ||||
(after tax adjustments): | ||||
Item that may be reclassified subsequently to | ||||
profit or loss: | ||||
Exchange differences on translation of | ||||
financial statements of foreign operations | (1,737) | (23) | ||
Share of other comprehensive income | ||||
of equity-accounted investees | 10,999 | 5,841 | ||
Other comprehensive income for the year | 9,262 | 5,818 | ||
Total comprehensive income for the year | 237,362 | 196,213 | ||
2016 | 2015 | |||
Note | RMB'000 | RMB'000 | ||
Profit attributable to: | ||||
Equity shareholders of the Company | 228,101 | 190,393 | ||
Non-controlling interests | (1) | 2 | ||
Profit for the year | 228,100 | 190,395 | ||
Total comprehensive income attributable to: | ||||
Equity shareholders of the Company | 237,358 | 196,211 | ||
Non-controlling interests | 4 | 2 | ||
Total comprehensive income for the year | 237,362 | 196,213 | ||
Earnings per share (RMB) | ||||
Basic | 8(a) | 0.630 | 0.565 | |
Diluted | 8(b) | 0.620 | 0.553 | |
2016 | 2015 | |||
Note | RMB'000 | RMB'000 | ||
Non-current assets | ||||
Property, plant and equipment, net | 9 | 331,994 | 362,731 | |
Construction in progress | 16,768 | 5,383 | ||
Intangible assets | 10 | 199,492 | 208,093 | |
Lease prepayments | 57,852 | 59,161 | ||
Interest in associates | 11 | 278,642 | 240,949 | |
Interest in a joint venture | 17,862 | - | ||
Deferred tax assets | 10,864 | 11,615 | ||
Other non-current assets | 125,775 | 35,723 | ||
Total non-current assets | 1,039,249 | 923,655 | ||
Current assets | ||||
Inventories | 178,702 | 117,592 | ||
Trade and other receivables | 12 | 324,436 | 251,874 | |
Restricted cash | 230,000 | 255,000 | ||
Cash and cash equivalents | 646,887 | 651,050 | ||
Total current assets | 1,380,025 | 1,275,516 | ||
Current liabilities | ||||
Bank loans | 220,000 | 472,873 | ||
Trade and other payables | 13 | 77,018 | 117,801 | |
Current portion of preferred shares | 12,461 | 11,538 | ||
Income tax payable | 18,860 | 21,888 | ||
Total current liabilities | 328,339 | 624,100 | ||
Net current assets | 1,051,686 | 651,416 | ||
Total assets less current liabilities | 2,090,935 | 1,575,071 | ||
Bloomage BioTechnology Corporation Ltd. published this content on 22 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 March 2017 15:10:11 UTC.
Original documenthttp://www.bloomagebio-tech.com/attachment/2017032223020100002754382_en.pdf
Public permalinkhttp://www.publicnow.com/view/AA56432DAD3C223ED125B7F72770A3FF86667007
